Double success for innovative ‘child-friendly’ HIV treatment

Published on


University of Liverpool’s Nanomedicine research has been recognised by The (US) President’s Emergency Plan for AIDS Relief and a fundraising campaign to help improve drug therapies for children with HIV has reached its target in record time.

Researchers from the University, led by Professors Andrew Owen and Steve Rannard from the University’s Nanomedicine Partnership, are developing lower-dose adult formulations and child-friendly treatments for HIV using Solid Drug Nanoparticle (SDN) technology, which can be dispersed in water not dissolved in alcohol.

These new treatments aim to reduce the doses required and increase the number of people treated from the same drug supply – reducing costs for cash-strapped charities working on the ground.


Despite having a product ready for clinical trials funding was needed to support the next steps of paediatric clinical development.

In the Spring of 2017 the University’s Development and Alumni Relations team launched a fundraising appeal with the aim of raising £400K to translate this new medicine as soon as possible.

Thanks to the generosity of donors this fundraising target was met this month.


Another milestone for the team is the inclusion of the formulations in the 2019 update of The (US) President’s Emergency Plan for AIDS Relief (PEPFAR) antiretroviral formulation prioritization list for low- and middle-income countries.

PEPFAR is a United States governmental initiative to address the global HIV/AIDS epidemic and help save the lives of those suffering from the disease, primarily in Africa. The inclusion of the formulation on this list is an essential step towards this research reaching the millions of people who need it.

Next steps

Professor Steve Rannard, said: “Thank you to all of our supporters as every donation made to the appeal is greatly appreciated by the team. Your gifts are vital and will fund essential research that will enable us to get these new options to those who need it the most.”

Professor Andrew Owen, adds: “Our next steps are a manufacturing run and clinical trial, with a focus on paediatric nanomedicine. A high priority for us is to make these options widely available as cheaply as possible and our unique partnership with the Medicine Patent Pool will seek to make that happen.”

Our work doesn’t stop here

You may have already heard about our exciting new development on campus, which will greatly enhance not only the wellbeing of our students, but also the cultural life of the city.

A new teaching and performance centre, soon to break ground on the south side of campus, will house a 400-seat performance auditorium with space for a 70-piece orchestra as well as three lecture theatres with a capacity for more than 1,000 students, and multiple smaller seminar facilities. Not only will students from all disciplines be able to learn, work, perform and enjoy this fantastic space, but alongside community groups and organisations, we aspire for this centre to contribute to Liverpool’s vibrant cultural offering.

It’s truly a symphony in the making but we need your help to finish it. You can find out more about the project on our dedicated pages here: